Miora Technology Overview
Critical Need
The maternal morbidity rate in the United States and around the world poses a significant health challenge. The U.S. experiences higher rates of maternal morbidity and mortality compared to other developed countries, with complications arising from conditions like gestational diabetes mellitus (GDM) and preeclampsia. Globally, the risk is even more pronounced, with limited access to quality healthcare exacerbating the situation.
This disparity underscores the urgent need for innovative solutions and better research to support maternal health. Improving diagnostic tools, providing evidence-based interventions, and enhancing structural support for expectant and new mothers are critical to addressing these risks and improving health outcomes for women and their infants worldwide.
Technology Innovation
At Miora, we are committed to addressing these critical needs with innovative technology solutions aimed at improving maternal and infant health. Our advancements include:
- Microbiome AI for Early Diagnosis: Our cutting-edge diagnostics and wellness tests assess the microbiome balance for pregnant women through AI deep learning, facilitating the early detection of gestational diabetes mellitus (GDM) and other pregnancy-associated conditions.
- Tailored Intervention: This includes personalized nutrition plans, probiotics, and prebiotics, to optimize the gut microbiome, and prevent disease onset and progression during pregnancy.
Substantial Impact
By leveraging Miora’s cutting-edge technology, we can significantly improve maternal and infant health outcomes while reducing healthcare-related costs. Early diagnosis of conditions such as GDM and preeclampsia through AI-powered microbiome analysis enables timely interventions, preventing complications that often lead to expensive hospitalizations and intensive treatments.
By shifting the focus from reactive treatment to proactive prevention, Miora’s technology not only enhances the well-being of mothers and infants but also alleviates financial strain on healthcare systems, insurers, and families, making high-quality maternal care more accessible and sustainable.
Clinical Research
Gestational Diabetes Mellitus (GDM) in Pregnant Women
ClinicalTrials.gov ID: NCT05265741
Study Overview
Brief Summary: The purpose of the trial is to discover and predict the development of GDM in pregnant women in their first trimester.
Detailed Description
Gestational Diabetes Mellitus (GDM) is a type of diabetes that affects pregnant women and often develops in the middle and later stages of pregnancy. GDM can lead to adverse maternal outcomes such as preeclampsia, postpartum hemorrhage, and undesirable infant outcomes such as macrosomia and neonatal hypoglycemia. GDM also increases the risk of long-term consequences such as the development of type 2 diabetes in mothers, metabolic syndrome, and cardiovascular diseases.
Gut microbiota has been shown to play a significant role in the etiology of metabolic illnesses, and recent studies have demonstrated that the gut microbiota of GDM women is altered compared to those of healthy women.
This trial aims to identify biomarkers during the first trimester (week 8-week 12) that can predict the likelihood of developing GDM while also examining potential links between GDM and gut microbiota. To achieve these objectives, the investigators have designed a trial that involves the collection of fecal samples from pregnant women for microbiome analysis at different stages of pregnancy. Although GDM is diagnosed at or after 24 weeks, the investigators will collect samples at the first, second, and third trimesters to determine if any alterations in the microbiome occur prior to symptom onset.
Our Partnerships
We are working with leading institutions to conduct groundbreaking research:
Publications
Exploring the Influence of Microbiota on Gestational Diabetes and Its Potential as a Biomarker
Suresh Bokoliya, Stephanie McClellan, Yanjiao Zhou, Nini Fan
University of Connecticut Health Center & Miora Inc.
Additional Research: